SAN DIEGO — People get excited about gene therapy for the potential to cure some pretty horrible diseases, but the safety risks that patients take on with the preparation and administration of these treatments are often overlooked.

On Saturday afternoon, Bluebird Bio (BLUE) reported for the first time the diagnosis of myelodysplastic syndrome (MDS), a cancer-like disease of the bone marrow, in a single sickle cell disease patient who had undergone treatment with the biotech’s Lentiglobin gene therapy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy